SEARCH

SEARCH BY CITATION

References

  • Abe M, Akbarzaderaleh P, Hamachi M, Yoshimoto N, Yamamoto S. 2010. Interaction mechanism of mono-PEGylated proteins in electrostatic interaction chromatography. Biotechnol J 5(5):477483.
  • Basu A, Yang K, Wang M. 2006. Structure–function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjug Chem 17(3):618630.
  • Bhambure R, Kumar K, Rathore AS. 2011. High-throughput process development for biopharmaceutical drug substances. Trends Biotechnol 29(3):127135.
  • Bonora GM, Drioli S. 2009. Reactive PEGs for protein conjugation. In: Veronese FM, editor, PEGylated protein drugs: Basic science and clinical applications. Basel, Boston, Berlin: Birkhäuser Verlag. p 3345.
  • Chaffee S, Mary A, Stiehm ER, Girault D, Fischer A, Hershfield MS. 1992. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J Clin Invest 89(5):16431651.
  • Fee CJ, Van Alstine JA. 2006. Peg-proteins: Reaction engineering and separation issues. Chem Eng Sci 61(3):924939.
  • Freitas D, Abrahao-Neto J. 2010. Biochemical and biophysical characterization of lysozyme modified by PEGylation. Int J Pharm 392(1–2):111117.
  • Gaberc-Porekar V, Zore I, Podobnik B, Menart V. 2008. Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr Opin Drug Discov Devel 11(2):242250.
  • Hansen SK, Maiser B, Hubbuch JJ. 2012. Rapid quantification of protein pegamers by multivariate evaluation of chromatographic data. J Chromatogr A 1257:4147.
  • Jevsevar S, Kunstelj M, Gaberc-Porekar V. 2010. Pegylation of therapeutic proteins. Biotechnol J 5(1):113128.
  • Kinstler OB, Brems DN, Lauren SL, Paige AG, Hamburger JB, Treuheit MJ. 1996. Characterization and stability of N-terminally PEGylated rhG-CSF. Pharm Res 13(7):9961002.
  • Leader B, Baca QJ, Golan DE. 2008. Protein therapeutics: A summary and pharmacological classification. Nat Rev Drug Discov 7(1):2139.
  • Lee YC, Yang D. 2002. Determination of lysozyme activities in a microplate format. Anal Biochem 310(2):223224.
  • Lee BK, Kwon JS, Kim HJ, Yamamoto S, Lee EK. 2007. Solid-phase PEGylation of recombinant interferon alpha-2a for site-specific modification: Process performance, characterization, and in vitro bioactivity. Bioconjug Chem 18(6):17281734.
  • Maiser B, Kröner F, Dismer F, Brenner-Weiß G, Hubbuch JJ. 2012. Isoform separation and binding site determination of mono-PEGylated lysozyme with pH gradient chromatography. J Chromatogr A 1268:102108.
  • Monkarsh SP, Ma Y, Aglione A, Bailon P, Ciolek D, DeBarbieri B, Graves MC, Hollfelder K, Michel H, Palleroni A, Porter JE, Russoman E, Roy S, Pan YC. 1997. Positional isomers of monopegylated interferon alpha-2a: Isolation, characterization, and biological activity. Anal Biochem 247(2):434440.
  • Moosmann A, Blath J, Lindner R, Müller E, Böttinger H. 2011. Aldehyde PEGylation kinetics: A standard protein versus a pharmaceutically relevant single chain variable fragment. Bioconjug Chem 22(8):15451558.
  • Morar AS, Schrimsher JL, Chavez MD. 2006. PEGylation of proteins: A structural approach. Biopharm Int 19(4):3646.
  • Oelmeier S, Dismer F, Hubbuch J. 2011. Application of an aqueous two-phase systems high-throughput screening method to evaluate mAb HCP separation. Biotechnol Bioeng 108(1):6981.
  • Ottow KE, Lund-Olesen T, Maury TL, Hansen MF, Hobley TJ. 2011. A magnetic adsorbent-based process for semi-continuous PEGylation of proteins. Biotechnol J 6(4):396409.
  • Pai S, Hammouda B, Hong K, Pozzo DC, Przybycien TM, Tilton RD. 2011. The conformation of the poly(ethylene glycol) chain in mono-pegylated lysozyme and mono-pegylated human growth hormone. Bioconjug Chem 22(11):23172323.
  • Palm T, Esfandiary R, Gandhi R. 2011. The effect of PEGylation on the stability of small therapeutic proteins. Pharm Dev Technol 16(5):441448.
  • Pasut G, Veronese FM. 2012. State of the art in PEGylation: The great versatility achieved after forty years of research. J Control Release 161(2):461472.
  • Payne R, Murphy B, Manning M. 2011. Product development issues for PEGylated proteins. Pharm Dev Technol 16(5):423440.
  • Roberts MJ, Harris JM. 1998. Attachment of degradable poly(ethylene glycol) to proteins has the potential to increase therapeutic efficacy. J Pharm Sci 87(11):14401445.
  • Roberts MJ, Bentley MD, Harris JM. 2002. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 54(4):459476.
  • Sato H. 2002. Enzymatic procedure for site-specific pegylation of proteins. Adv Drug Deliv Rev 54(4):487504.
  • Sergi M, Caboi F, Maullu C, Orsini G, Tonon G. 2009. Enzymatic techniques for PEGylation of biopharmaceuticals. In: Veronese FM, editor, PEGylated protein drugs: Basic science and clinical applications. Basel, Boston, Berlin: Birkhäuser Verlag. p 7588.
  • Shugar D. 1952. The measurement of lysozyme activity and the ultra-violet inactivation of lysozyme. Biochem Biophys Acta 8(3):302309.
  • Veronese FM, Pasut G. 2008. PEGylation: Posttranslational bioengineering of protein biotherapeutics. Drug Discov Today 5(2–3):e57e64.
  • Yang K, Basu A, Wang M, Chintala R, Hsieh M-C, Liu S, Hua J, Zhang Z, Zhou J, Li M., et al. 2003. Tailoring structure–function and pharmacokinetic properties of single-chain Fv proteins by site-specific pegylation. Protein Eng Des Sel 16(10):761770.